SOURCE: SpectraScience, Inc.

March 29, 2016 09:15 ET

SpectraScience Announces Second Shipment of WavSTAT4 Console to Leeds, England

Expanded Trial Exclusively for Nurse Practioners

SAN DIEGO, CA--(Marketwired - March 29, 2016) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that St. James Hospital in Leeds, England has requested an additional WavSTAT Optical Biopsy System© to be used by nurse endoscopists to generate data for the Medical Device Technology Approval Panel of the National Institute of Health and Clinical Excellence (NICE). Approval by NICE is a pre-condition for sales in the UK.

"In countries such as the UK where nurse endoscopists perform a significant number of the screening colonoscopies it is important their input be considered in gathering clinical data for the approval process. One of the key advantages of the WavSTAT system is its ability to provide a superior diagnostic capability to every level of clinician. We enable community physicians and nurse endoscopists to have a diagnostic capability that equals that of experts," said Michael Oliver, President and Chief Executive Officer of SpectraScience, Inc. "Our system is fast, easy to use and requires very little training for the clinician to become proficient. It enables the clinician to use the existing colonoscopy procedure. It provides the clinician with real-time, actionable diagnoses; is safer for the patient by eliminating unnecessary polypectomies and biopsies; and reduces the total cost of health care."

About SpectraScience, Inc.:

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.

For more information:

Visit our web site

Forward-Looking Statement for SpectraScience, Inc.

This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

Contact Information